Skip to main content
Evidence Snapshot

Retinoic acid receptor RXR-beta

CHEMBL1870 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:05:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1870
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor RXR-beta as ChEMBL target CHEMBL1870, mapped to UniProt P28702. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Retinoic acid receptor RXR-beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1870
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P28702
Retinoic acid receptor RXR-beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Retinoic acid receptor RXR-beta matters

As of 2026-09-13

Retinoic acid receptor RXR-beta is reviewed as Retinoic acid receptor RXR-beta (UniProt P28702); the current evidence base includes 9 approved drugs, 535 compounds, and 161 assays, with lead potency reaching pChEMBL 9.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 535 compounds, and 161 assays for this target. The dominant activity type is EC50. CHEMBL38 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL38 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 9.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Retinoic acid receptor RXR-beta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28702, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

535
Total Compounds
161
Total Assays
9
Approved Drugs
IC50: 43.0, KI: 104.0, EC50: 340.0, KD: 19.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL38
 9.3 Ki Approved
No preferred name
CHEMBL5404648
 9.2 EC50 —
No preferred name
CHEMBL75133
 9.1 EC50 Clinical
No preferred name
CHEMBL69091
 8.7 EC50 —
No preferred name
CHEMBL111589
 8.7 Ki —

Approved Drugs

Structure Compound First Approval
ALITRETINOIN
CHEMBL705
 1999
BEXAROTENE
CHEMBL1023
 1999
TRETINOIN
CHEMBL38
 1971
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:05:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1870